, Related to Figure 1: Human and mouse IL-2 receptor subunits crossreact, anti-IL-2 antibodies and antibody fragments induce similar signaling effects, and bivalent affinities of anti-IL-2 antibodies are >25-fold tighter than their respective monovalent affinities. (A) Surface plasmon resonance (SPR) equilibrium titrations of mouse or human IL-2Rα, IL-2Rβ, or IL-2Rγ subunits binding to either the mouse or human IL-2 cytokine. Fitted equilibrium dissociation constant (K d ) values are presented below, assuming first-order binding interactions. Note the formidable crossspecies reactivity for both the IL-2/IL-2Rα and hIL-2/IL-2Rβ interactions. IL-2Rγ does not bind IL-2 independently, but rather requires cooperativity with the IL-2Rβ subunit. (B) STAT5 phosphorylation response to either unbound mIL-2, mIL-2 pre-bound to the JES6-1 scFv, and mIL-2 pre-bound to the full JES6-1 antibody (Ab, left) or to unbound mIL-2, mIL-2 pre-bound to the S4B6 Fab, and mIL-2 pre-bound to the full S4B6 antibody (right) in IL-2Rα -(top) or IL-2Rα + (bottom) YT-1 human NK cells. Data are representative of three independent experiments. Fitted half maximal effective concentrations (EC 50 s) for each treatment condition are tabulated below. Note that antibody fragments exert the same effects on IL-2 signaling as do the full antibodies, but with attenuated potency due to their reduced affinities for the cytokine. (C) SPR equilibrium titrations of mIL-2 and hIL-2 binding to immobilized JES6-1 or S4B6 antibodies (top) and equilibrium titrations of bivalent JES6-1 and S4B6 antibodies binding to yeast surface-displayed mIL-2 and hIL-2 (bottom). Computed equilibrium dissociation constant (K d ) values are provided in the table below, assuming first-order binding interactions. Note that the mIL-2 affinities of the monovalent antibodies are >25-fold weaker than those of their bivalent counterparts. Also, hIL-2 has limited crossreactivity with S4B6 and no cross-reactivity with JES6-1. All error bars represent SD. Crystal structure of mIL-2 (dark gray) bound to the scFv fragment of JES6-1 with the variable heavy (VH, blue) and light (VL, magenta) chains indicated. (B) Crystal structure of mIL-2 (light gray) bound to the S4B6 Fab with the VH (orange), VL (green), constant heavy 1 (CH1, orange), and constant light (CL, green) chains denoted. (C)-(D) Detailed views of the mIL-2/JES6-1 (C) and mIL-2/S4B6 (D) interfaces (colored as in panels (A) and (B), respectively), with key interacting residues on the cytokine and antibody shown as sticks. The mIL-2/JES6-1 interface primarily comprises the mIL-2 A helix and AB loop and heavy chain (HC) complementarity determining region (CDR)-2, light chain (LC) CDR1, and LC CDR3 of JES6-1, whereas the mIL-2/S4B6 interface is localized to the mIL-2 B and C helices and HC CDR3 and LC CDR1 of S4B6. Black dashes represent hydrogen bonds and salt bridges. A coordinated water molecule is shown in brown. Crystallographic statistics for mIL-2/antibody complexes are provided in Table S1 . Figure S3 , Related to Figure 3: JES6-1 allosterically distorts the IL-2 structure proximal to the IL-2Rα binding site. JES6-1-bound mIL-2 (red), receptor-bound hIL-2 from the quaternary complex (PDB ID 2B5I, pink), and S4B6-bound mIL-2 (light gray) are aligned. Surface representations of IL-2Rα (cyan), IL-2Rβ (navy), and IL-2Rγ (gold) are provided for context. A detailed view of the main chains for the three aligned cytokines near the IL-2Rα binding site is presented at right. Note that the structures overlay well in all regions of the cytokine with the exception of the IL-2Rα-interacting AB loop, where the JES6-1-bound cytokine diverges drastically from the receptor-bound hIL-2, which overlays closely with the S4B6-bound mIL-2. JES6-1-induced distortion of the AB loop disrupts binding of IL-2Rα in the presence of the antibody. and receptor-bound hIL-2 from the quaternary complex structure (PDB 2B5I, pink) are overlaid with surface renderings of the IL-2Rα (cyan), IL-2Rβ (navy), and IL-2Rγ (gold) subunits shown for context. Critical hIL-2 residues involved in the hIL-2/IL-2Rβ interaction are labeled, as are their mIL-2 counterparts in the S4B6-bound structure. Note the similarity between the antibody-bound and receptor-bound cytokine structures in the vicinity of the IL-2Rβ binding site (the A and C helices of the cytokine). (B) Overlay of the mIL-2/S4B6 and hIL-2 quaternary complex structures, colored as in (A), with surface representations of the S4B6 variable heavy (VH, orange) and light (VL, green) chains also shown. The predicted clash between the S4B6 LC CDR1 and domain 1 of IL-2Rβ is indicated with a red dashed line. This unfavorable interaction is predicted to hinder IL-2/IL-2Rβ association when the S4B6 antibody is bound to the cytokine. represent unique antibody (Ab):receptor ratios. Note the fundamental differences in the JES6-1-and S4B6-bound cytokine interactions with the receptor subunits: mIL-2 exhibits an increased mIL-2Rα dissociation rate with increasing JES6-1:mIL-2 ratios whereas mIL-2 loses binding to mIL-2Rα when S4B6:mIL-2 ratios exceed 0.4:1, and mIL-2 binding to mIL-2Rβ is drastically reduced between JES6-1:mIL-2 ratios of 0.13:1 and 0.32:1 whereas mIL-2 simultaneously binds mIL-2Rβ and S4B6. SPR kinetic profiles for mIL-2 interactions with immobilized mIL-2Rα (E) or mIL-2Rβ (F), soluble mIL-2Rα (G) or mIL-2Rβ (H) interactions with immobilized mIL-2/JES6-1 immunocomplex, and soluble mIL-2Rα (I) or mIL-2Rβ (J) interactions with immobilized mIL-2/S4B6 immunocomplex are also shown. Individual curves in panels (E)-(J) represent unique concentrations of the soluble species. JES6-1 accelerates the dissociation rate of the mIL-2/mIL-2Rα complex whereas S4B6 blocks mIL-2/mIL-2Rα complex formation altogether and JES6-1 abrogates mIL-2/mIL-2Rβ binding whereas S4B6 slows both the association and dissociation rates of the mIL-2/mIL-2Rβ complex. hi Treg cells (left), S4B6-bound mIL-2 is sterically obstructed from binding to the IL-2Rα subunit but is primed for binding to the IL-2Rβ subunit and forms the IL-2 ternary complex. On IL-2Rα lo effector cells (right), S4B6-bound mIL-2 also forms the IL-2 ternary complex. Thus, S4B6-bound mIL-2 stimulates growth of both IL-2Rα hi and IL-2Rα lo cells, and immunocomplex sensitivity is determined by IL-2Rβ expression, favoring potentiation of IL-2Rβ hi effector cells. hIL-2 (amino acids 1-133), hIL-2Rα ectodomain (amino acids 1-217), hIL-2Rβ ectodomain (amino acids 1-214), hIL-2Rγ ectodomain (amino acids 1-232), mIL-2Rα ectodomain (amino acids 1-213), mIL-2Rβ ectodomain (amino acids 1-215), and mIL-2Rγ ectodomain (amino acids 34-233) were secreted and purified using a baculovirus expression system, as previously described (Wang et al., 2005) . All proteins were purified to >98% homogeneity with a Superdex 200 sizing column (GE Healthcare) equilibrated in HBS.
For biotinylated protein expression, human or mouse IL-2 receptor subunits with Cterminal biotin acceptor peptides (BAP)-LNDIFEAQKIEWHE were expressed and purified via Ni-NTA affinity chromatography and then biotinylated with the soluble BirA ligase enzyme in 0.5 mM Bicine pH 8.3, 100 mM ATP, 100 mM magnesium acetate, and 500 mM biotin (Sigma). Excess biotin was removed by size exclusion chromatography on a Superdex 200 column equilibrated in HBS.
The JES6-1 hybridoma cell line (Abrams et al., 1992) was kindly provided by Onur
Boyman and the S4B6 hybridoma cell line (Zurawski et al., 1986 ) (commercially available as ATCC clone HB-10968) was obtained. The variable heavy (VH) and light (VL) chains of both JES6-1 and S4B6 were cloned out of their respective hybridoma cell lines by isolating and reverse transcribing DNA and subsequently extracting the variable chains via PCR using conserved rat IgG2A framework and constant domain primers for the HC and conserved rat kappa framework and constant domain primers for the LC, as described previously (Dubel et al., 1994) . Antibody variable domain framework and CDR regions were delineated using the International Immunogenetics Information System (IMGT) V-QUEST tool (Brochet et al., 2008; Giudicelli et al., 2011) . For JES6-1 scFv expression, the identified antibody VH and VL domains separated by a (Gly 4 Ser) 3 linker were cloned into the pAcGP67A vector for transfection. For S4B6 Fab expression, the identified VH followed by the rat IgG2A constant heavy 1 (CH1) domain and the identified VL domain followed by the rat kappa constant light (CL) domain were separately cloned into the pAcGP67A plasmid containing 3C protease-cleavable basic and acidic leucine zippers, respectively, for high-fidelity pairing of the Fab chains, as detailed previously (Bankovich et al., 2007; Chang et al., 1994) . The S4B6 Fab HC and LC constructs were transfected independently and their corresponding viruses were cotitrated to determine optimal infection ratios for equivalent expression of the two chains.
Insect cell secretion and purification of the JES6-1 scFv and the S4B6 Fab proceeded as described for IL-2 cytokine and receptor subunits. The S4B6 Fab was treated with 3C to remove the leucine zippers prior to FPLC purification.
Full-length JES6-1 antibody was purchased commercially (eBioscience) and full-length S4B6 antibody, secreted and purified from the publicly available hybridoma cell line, was generously provided by Onur Boyman. For surface plasmon resonance (SPR) studies, antibodies were biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation kit (Pierce)
according to the manufacturer's protocol.
Cell Lines. Unmodified YT-1 (Yodoi et al., 1985) and IL-2Rα + YT-1 human natural killer cells (Kuziel et al., 1993) were cultured in RPMI complete medium (RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, minimum nonessential amino acids, sodium pyruvate, 25 mM HEPES, and penicillin-streptomycin [Gibco] ) and maintained at 37º C in a humidified atmosphere with 5% CO 2 .
The subpopulation of YT-1 cells expressing IL-2Rα was purified via magnetic selection as detailed previously (Ring et al., 2012) . The remaining four pretreated mice from each cohort were administered 3% DSS (MP Biomedicals Inc.) in their drinking water beginning on day 8 to induce colitis. On day 15, disease severity was assessed by a clinical disease activity index. CDAI was calculated on day 15 as described previously (Cooper et al., 1993) , using the following parameters: body weight decrease (0= no change to 4 = >20% change); stool consistency (0 = solid to 4 = liquid stools that stick to the anus); and bleeding (0 = none to 4 = gross bleeding). Scores for each parameter were summed and divided by three to determine CDAI. On day 16, mice were sacrificed and their entire colons were removed (from cecum to anus). Colon length was measured and shortening was used as an indirect marker of inflammation. Histological scoring of paraffin-embedded and hematoxylin and eosin-stained transversal colon sections was implemented in a blinded manner using a weighted score, ranging from 0 (no signs of inflammation) to 3 (severe inflammation).
The final histological score was calculated as the mean score from 4 independently analyzed sections from each sample. One representative section from each condition is shown. The "no disease" cohort refers to an untreated group of mice in which colitis was not induced. Statistical significance was determined by either Student's t-test (colon length) or by Mann-Whitney U test (histological grade and disease activity score).
Yeast surface and SPR affinity titrations. For yeast studies, full-length human and mouse IL-2 were cloned into the pCT302 vector and presented on the surface of yeast as described previously (Boder and Wittrup, 1997; Rao et al., 2004) . Yeast displaying hIL-2 and mIL-2 were incubated in FACS buffer containing serial dilutions of the full-length flow, regeneration, and analysis conditions were as described for SPR affinity titrations.
